Minneapolis-based Celcuity Inc. is a clinical stage biotechnology company that specializes in developing molecularly targeted therapies for cancer patients across the United States. Its CELsignia diagnostic platform harnesses a patient's living tumor cells to pinpoint the specific abnormal cellular process behind each patient's cancer and to identify the relevant targeted therapy options for a successful treatment. Among its drug candidates is Gedatolisib, which selectively targets several class I isoforms of PI3K and mammalian target of rapamycin to offer advanced therapeutic care for patients with hormone receptor positive, HER2-negative and advanced or metastatic breast cancer. Celcuity is also working on its CELsignia MP Test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company holds a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Launched in 2011, Celcuity aims to be at the forefront of the biotechnology industry innovations with its disease-targeting therapies.
Celcuity's ticker is CELC
The company's shares trade on the NASDAQ stock exchange
They are based in Minneapolis, Minnesota
There are 11-50 employees working at Celcuity
It is celcuity.com
Celcuity is in the Healthcare sector
Celcuity is in the Biotechnology industry
The following five companies are Celcuity's industry peers: